Solid Biosciences (SLDB)
NASDAQ:SLDB
Want to see SLDB full AI Analyst Report?
SLDB Stock Chart & Stats
$8.63
$0.18(4.59%)
At close: 4:00 PM EST
$8.63
$0.18(4.59%)
Day’s Range― - ―
52-Week Range$3.34 - $8.87
Previous CloseN/A
Volume1.97M
Average Volume (3M)1.08M
Market Cap
$722.62M
Enterprise Value$294.79M
Total Cash (Recent Filing)$381.32M
Total Debt (Recent Filing)$20.67M
Price to Earnings (P/E)―
Beta1.76
Next Earnings
Aug 17, 2026EPS Estimate
-0.45Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-1.95
Shares Outstanding98,449,610
10 Day Avg. Volume1,130,920
30 Day Avg. Volume1,076,557
Financial Highlights & Ratios
PEG Ratio0.08
Price to Book (P/B)2.74
Price to Sales (P/S)0.00
P/FCF Ratio-3.13
Enterprise Value/Market Cap0.41
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit-377.45
Enterprise Value/Ebitda-1.55
Forecast
1Y Price Target
$17.22Price Target Upside99.56% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering11
EPS Forecast (FY)-1.91
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Contract Manufacturing Services (Solid Biologics)The majority-owned Solid Biologics business offers durable, fee-for-service revenue from AAV process development and GMP manufacturing. This service line diversifies cash generation away from binary drug approvals, supports recurring customer demand in gene therapy, and underpins medium-term operational resilience.
Encouraging Phase 1/2 Data And FDA AlignmentRobust early human transduction and biomarker signals plus FDA agreement on Phase 3 design materially improve clinical and regulatory visibility. A clearer registrational path reduces program execution risk, aids partner/licensing discussions, and increases the likelihood of a revenue-producing asset over the medium term.
$240M Private Placement Extends RunwayThe sizable financing materially lengthens the company's cash runway, lowering immediate liquidity pressure and allowing further investment in Phase 3 and manufacturing scale-up. While not guaranteed to fund full development, this capital reduces near-term financing risk and supports strategic execution for the next 18+ months.
Bears Say
Minimal Revenue With Widening LossesThe company lacks product-derived revenue and is reporting materially widening net losses, which weakens internal funding capacity and increases reliance on external capital. Persistent operating deficits degrade financial flexibility and raise dilution risk if development timelines slip or costs rise.
High Cash Burn And Negative Free Cash FlowConsistently large negative free cash flow means the business consumes substantial cash to advance programs. This sustained burn rate forces recurrent financings, constrains strategic investments, and creates execution risk if capital markets tighten or clinical setbacks increase funding needs.
Reliance On External Financing And Equity VolatilityVolatile equity driven by capital raises indicates the company funds operations primarily through external financings. Repeated equity issuance can dilute shareholders, complicate governance, and leave the company vulnerable if future raises become more costly or restricted, especially before product revenue emerges.
Solid Biosciences News
SLDB FAQ
What was Solid Biosciences’s price range in the past 12 months?
Solid Biosciences lowest stock price was $3.33 and its highest was $8.87 in the past 12 months.
What is Solid Biosciences’s market cap?
Solid Biosciences’s market cap is $722.62M.
When is Solid Biosciences’s upcoming earnings report date?
Solid Biosciences’s upcoming earnings report date is Aug 17, 2026 which is in 76 days.
How were Solid Biosciences’s earnings last quarter?
Solid Biosciences released its earnings results on May 12, 2026. The company reported -$0.52 earnings per share for the quarter, missing the consensus estimate of -$0.429 by -$0.091.
Is Solid Biosciences overvalued?
According to Wall Street analysts Solid Biosciences’s price is currently Undervalued.
Does Solid Biosciences pay dividends?
Solid Biosciences does not currently pay dividends.
What is Solid Biosciences’s EPS estimate?
Solid Biosciences’s EPS estimate is -0.45.
How many shares outstanding does Solid Biosciences have?
Solid Biosciences has 98,449,610 shares outstanding.
What happened to Solid Biosciences’s price movement after its last earnings report?
Solid Biosciences reported an EPS of -$0.52 in its last earnings report, missing expectations of -$0.429. Following the earnings report the stock price went down -4.404%.
Which hedge fund is a major shareholder of Solid Biosciences?
Currently, no hedge funds are holding shares in SLDB
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Solid Biosciences Stock Smart Score
Outperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$17.22 (99.56% Upside)
$17.22 (99.56% Upside)
Blogger Sentiment
Bullish
SLDB Sentiment 70%
Sector Average ―
Sector Average ―
Hedge Fund Trend
Increased
By 4.1M Shares
Last Quarter.
Last Quarter.
Crowd Wisdom
Very Negative
Last 7 Days ▼ 1.1%
Last 30 Days ▼ 2.0%
Last 30 Days ▼ 2.0%
Technicals
SMA
Positive
20 days / 200 days
Momentum
123.98%
12-Months-Change
Fundamentals
Return on Equity
-74.45%
Trailing 12-Months
Asset Growth
22.97%
Trailing 12-Months
Company Description
Solid Biosciences
Solid Biosciences Inc. engages in developing therapies for duchenne muscular dystrophy in the United States. The company's lead product candidate is SGT-001, a gene transfer candidate, which is in a Phase I/II clinical trial to drive functional dystrophin protein expression in patients' muscles; and SGT-003, a ext-generation gene transfer candidate for the treatment of duchenne muscular dystrophy. It also engages in developing of platform technologies, including dual gene expression, a technology for packaging multiple transgenes into one vector, as well as novel capsids. The company has collaboration and license agreement with Ultragenyx Pharmaceutical Inc. to develop and commercialize new gene therapies for Duchenne Muscular Dystrophy. Solid Biosciences Inc. was incorporated in 2013 and is headquartered in Cambridge, Massachusetts.
SLDB Stock 12 Month Forecast
Average Price Target
$17.22
▲(99.56% Upside)
Technical Analysis
Ownership Overview
13.16% Insiders
9.50% Mutual Funds
65.03% Other Institutional Investors
4.96% Public Companies and
Individual Investors
Options Prices
Currently, No data available
---